Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

Adaptimmune to Present at Upcoming CAR-TCR Summit; CEO James Noble to be a Keynote Speaker


Posted on: 30 Aug 17

PHILADELPHIA and OXFORD, U.K., Aug. 30, 2017 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in the use of TCR engineered T-cell therapy to treat cancer, today announced its participation in the CAR-TCR Summit in Boston on Tuesday, September 5, and Wednesday, September 6 at the Seaport Hotel & World Trade Center; One Seaport Lane, Boston, MA 02210.

The CAR-TCR summit highlights leaders in the CAR-T and TCR space to create a platform for cell immunotherapy experts to learn, network, and find solutions to their shared challenges. Adaptimmune’s representatives will give the following presentations:

  • James Noble, Adaptimmune’s Chief Executive Officer, will be a keynote speaker in the Industry Leaders’ Fireside Chat on Wednesday, September 6, 2017 from 8:45AM EDT-10:15AM EDT.
  • Samik Basu, Adaptimmune’s Director of Translational Science Research, will present at the Pre-Summit Deep Dive Day on Tuesday, September 5, 2017 from 3:00PM EDT-5:00PM EDT (Session G). He will discuss Understanding and Overcoming the Tumor Microenvironment.
  • Helen Tayton-Martin, Adaptimmune’s Chief Business Officer, will present on Wednesday, September 6, 2017 from 11:50AM EDT-12:20PM EDT (CAR-TCR Commercialization Stream). She will discuss Building a Commercial Engineered T-Cell Therapy Strategy.
  • Michael Blackton, Adaptimmune’s Vice President of Quality Assurance and CMC, will present on Wednesday, September 6, 2017 from 2:25PM EDT-2:55PM EDT (CAR-TCR Manufacturing Stream). He will discuss Applying Lifecycle Concepts to Advanced Stage T-Cell Product Development.

About Adaptimmune
Adaptimmune is a clinical-stage biopharmaceutical company focused on the development of novel cancer immunotherapy products. The Company’s unique SPEAR (Specific Peptide Enhanced Affinity Receptor) T‑cell platform enables the engineering of T-cells to target and destroy cancer, including solid tumors. Adaptimmune has a number of proprietary clinical programs, and is also developing its NY-ESO SPEAR T-cell program under a strategic collaboration and license agreement with GlaxoSmithKline. The Company is located in Philadelphia, USA and Oxfordshire, U.K. For more information, please visit http://www.adaptimmune.com

Forward-Looking Statements
This release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 (PSLRA). These forward-looking statements involve certain risks and uncertainties. Such risks and uncertainties could cause our actual results to differ materially from those indicated by such forward-looking statements, and include, without limitation: the success, cost and timing of our product development activities and clinical trials and our ability to successfully advance our TCR therapeutic candidates through the regulatory and commercialization processes. For a further description of the risks and uncertainties that could cause our actual results to differ materially from those expressed in these forward-looking statements, as well as risks relating to our business in general, we refer you to our Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (SEC) on August 3, 2017, and our other SEC filings. The forward-looking statements contained in this press release speak only as of the date the statements were made and we do not undertake any obligation to update such forward-looking statements to reflect subsequent events or circumstances.

CONTACT: Adaptimmune Contacts Investor Relations Juli P. Miller, Ph.D. T: (215) 825-9310 E: juli.miller@adaptimmune.com Media Relations Margaret Henry T: +44 (0)1235 430036 Cell: +44 (0)7710 304249 E: margaret.henry@adaptimmune.comGlobeNewswire
globenewswire.com

Last updated on: 30/08/2017

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.